As pivotal trials of Astrazeneca's Covid-19 antibody get underway, the company hopes that a longer half-life and more convenient dosing will set the project apart.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,